Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR010778)
Formula Reactant Zanubrutinib Metabolite M3/M11 Product Zanubrutinib Metabolite M2
Reactant Info Product Info
Metabolic Type Unclear - Unclear
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010777 Zanubrutinib Metabolite M9 Zanubrutinib Metabolite M3/M11 Unclear - Unclear zanubrutinib [1]
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010779 Zanubrutinib Metabolite M3/M11 Zanubrutinib Metabolite M10 Unclear - Unclear zanubrutinib [1]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010785 Naloxone Naloxone Metabolite M2 Unclear - Unclear Naloxone [2]
MR001898 Oxymorphone Noroxymorphone Oxidation - N-Demethylation Oxymorphone [3]
MR001878 Noroxycodone Noroxymorphone Oxidation - N-Demethylation Oxycodone hydrochloride [4], [5]
MR013819 Noroxycodone Noroxymorphone Unclear - Unclear Oxycodone [6]
MR001886 Oxymorphone Noroxymorphone Oxidation - N-Demethylation Oxycodone hydrochloride [7]
MR013821 Oxymorphone Noroxymorphone Unclear - Unclear Oxycodone [6]
⏷ Show the Full List of MR
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010786 Naloxone Metabolite M2 Naloxone Metabolite M35 Unclear - Unclear Naloxone [2]
MR010780 Zanubrutinib Metabolite M2 Zanubrutinib Metabolite M1 Unclear - Unclear zanubrutinib [1]
References
1 In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
2 Optimization of Mass Spectrometry Imaging for Drug Metabolism and Distribution Studies in the Zebrafish Larvae Model: A Case Study with the Opioid Antagonist Naloxone
3 Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
4 Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
5 Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer. Clin Pharmacokinet. 2023 May 10. doi: 10.1007/s40262-023-01255-1.
6 Metabolism and Disposition of Prescription Opioids: A Review
7 DrugBank(Pharmacology-Metabolism)Oxycodone hydrochloride

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.